Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan Denosumab Prior Auth | Open…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Denosumab (Prolia, Xgeva, and Biosimilars) for Subcutaneous Injection

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Part B coverage and prior authorization for physician-administered subcutaneous denosumab, including Prolia, Xgeva, and listed biosimilars, for Medicare Advantage members receiving treatment for osteoporosis, cancer-related fracture prevention, multiple myeloma or solid-tumor bone metastases, giant cell tumor of bone, or hypercalcemia of malignancy.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyDenosumab (Prolia, Xgeva, and Biosimilars)
    Policy CodePolicy N/A
    Change TypeAdded covered biosimilars
    Effective DateApril 9, 2026
    Last ReviewMay 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for physician-administered Prolia, Xgeva, or an eligible denosumab biosimilar.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added the Enoby, Xtrenbo, Bosaya, and Aukelso denosumab biosimilars.

    60 mg/6 mo

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Prolia maximum dose
    120 mg/4 wkXgeva maximum dose
    6 monthsInitial authorization
    12 monthsReauthorization
    ≥7.5 mg/dayGlucocorticoid threshold
    >12.5 mg/dLCalcium threshold

    Covered Indications and General Criteria

    Osteoporosis

    Covered when ALL of the following are met.

    • Product and diagnosis

      • Request is for Prolia or a denosumab biosimilar.
      • Diagnosis and qualifying pathway

        • Very high fracture risk

          • Member has postmenopausal, glucocorticoid-induced, or male osteoporosis and a BMD T-score at the hip or spine of ≤ -3.5.
          • Member has postmenopausal, glucocorticoid-induced, or male osteoporosis, a BMD T-score at the hip or spine of ≤ -2.5, and a major osteoporotic fracture, such as a hip, spine, forearm, wrist, or humerus fracture.
        • Prior bisphosphonate therapy: Member has completed a three-year trial of bisphosphonate therapy at up to maximally indicated doses, unless contraindications or clinically significant adverse effects occurred with both intravenous and oral formulations.3 years

          Alendronate is preferred.

    • Age and dosing requirements

      • Member is age 18 or older or has documentation of closed epiphyses on x-ray.
      • Prolia is not prescribed concurrently with Xgeva.
      • Dose does not exceed 60 mg every six months.60 mg every 6 months

    Cancer-Related Fracture Prevention

    Covered when ALL of the following are met.

    • Request is for Prolia or a denosumab biosimilar.
    • Qualifying cancer diagnosis and treatment

      • Member has prostate cancer and is receiving androgen-deprivation therapy, such as leuprolide, bicalutamide, or nilandron.
      • Member has breast cancer and is receiving adjuvant endocrine therapy, such as tamoxifen or an aromatase inhibitor including anastrozole, exemestane, or letrozole.
    • Treatment is prescribed by or in consultation with an oncologist.
    • Member is age 18 or older or has documentation of closed epiphyses on x-ray.

    Multiple Myeloma or Solid Tumor

    Covered when ALL of the following are met.

    • Request is for Xgeva or a denosumab biosimilar.
    • Qualifying diagnosis

      • Member has multiple myeloma.
      • Member has bony metastasis from a solid tumor, such as breast, kidney, lung, prostate, or thyroid cancer.
    • Member is at risk for a skeletal-related event, such as pathologic fracture, radiation therapy or surgery to bone, or spinal cord compression.
    • Treatment is prescribed by or in consultation with an oncologist.

    Giant Cell Tumor of Bone

    Covered when ALL of the following are met.

    • Request is for Xgeva or a denosumab biosimilar.
    • Disease status and treatment setting

      • Member has metastatic or unresectable giant cell tumor of bone.
      • Member has localized giant cell tumor of bone and Xgeva is prescribed as a single agent or in combination with interferon alfa or radiation therapy.
    • Treatment is prescribed by or in consultation with an oncologist.
    • Member is age 18 or older or has documentation of closed epiphyses on x-ray.

    Hypercalcemia of Malignancy

    Covered when ALL of the following are met.

    • Request is for Xgeva or a denosumab biosimilar.
    • Member has hypercalcemia of malignancy.
    • Treatment is prescribed by or in consultation with an oncologist.
    • Member is age 18 or older or has documentation of closed epiphyses on x-ray.
    • Albumin-corrected calcium is greater than 12.5 mg/dL despite intravenous bisphosphonate therapy in the last 30 days.> 12.5 mg/dL after IV bisphosphonate therapy within 30 days

    Concurrent use of Prolia and Xgeva is excluded from coverage. The requested denosumab product must be used under the applicable indication-specific criteria without concurrent administration of the other product.

    Coverage is not available when the member has systemic hypersensitivity to denosumab or any component of the formulation, preexisting hypocalcemia, or pregnancy.

    Covered Billing and Clinical Coding

    Covered HCPCS CodesHCPCSCovered
    Q5161Injection, denosumab-kyqq, biosimilar, 1 mg
    C9399Unclassified drugs or biologicals
    J3590Unclassified biologics
    Q5158Injection, denosumab-bnht, biosimilar, 1 mg
    Q5136Injection, denosumab-bbdz, biosimilar, 1 mg
    Q5157Injection, denosumab-bmwo, biosimilar, 1 mg
    Q5159Injection, denosumab-dssb, biosimilar, 1 mg
    Covered CPT Procedural CodesCPTCovered
    96372Subcutaneous or IM injection administration (therapeutic)
    96401Chemotherapy administration, subcutaneous or IM
    Covered NDC CodesNDCCovered
    83257-030-11Aukelso, 10-digit NDC
    83257-0030-11Aukelso, 11-digit NDC
    78206-195-01Bilprevda, 10-digit NDC
    78206-0195-01Bilprevda, 11-digit NDC
    78206-193-01Bildyos, 10-digit NDC
    78206-0193-01Bildyos, 11-digit NDC
    65219-670-01Bomyntra single-dose vial, 10-digit NDC
    65219-0670-01Bomyntra single-dose vial, 11-digit NDC
    65219-672-01Bomyntra prefilled syringe, 10-digit NDC
    65219-0672-01Bomyntra prefilled syringe, 11-digit NDC
    1–10 of 28
    1/3
    Very High Fracture Risk by BMD
    BMD measurement siteHip or spine
    T-score threshold≤ -3.5
    Coverage pathwayVery high fracture risk based on bone mineral density
    Very High Fracture Risk With Fracture
    BMD measurement siteHip or spine
    T-score threshold≤ -2.5
    Additional requirement

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Part B Denosumab Prior Authorization

    Prior authorization is required for physician-administered denosumab products covered under Part B. Requests must document that administration will occur in an approved medical setting and that the applicable indication-specific criteria are met.

    • Applicable products include Prolia or biosimilar products and Xgeva or biosimilar products.
    • Administration must be physician administered in-office or in a hospital outpatient department (HOPD).
    Documentation Required

    Meet Indication-Specific Authorization Criteria

    Authorize denosumab only when the requested product, diagnosis, administration setting, specialist involvement, age or skeletal-maturity requirements, dosing, and other indication-specific conditions are documented.

    • Prolia or biosimilar products are used for osteoporosis and prostate/breast cancer fracture prevention.

    Clinical Background

    Denosumab is a RANK ligand (RANKL) inhibitor administered by subcutaneous injection. The policy recognizes two principal treatment patterns: Prolia is used for osteoporosis and selected cancer-treatment-related bone loss and is generally administered at 60 mg every six months; Xgeva is used for skeletal complications associated with malignancy, giant cell tumor of bone, and hypercalcemia of malignancy and is generally administered at 120 mg every four weeks, with additional doses on days 8 and 15 of the first month for specified indications. Coverage includes the originator products and listed denosumab biosimilars when administered by a healthcare professional.

    Key Definitions

    Denosumab
    Drug classRANK ligand (RANKL) inhibitor
    AdministrationSubcutaneous injection
    ProductsProlia, Xgeva, and listed denosumab biosimilars
    Osteoporosis Coverage
    Postmenopausal osteoporosisCovered for patients at high or very high risk for fracture, or who have failed or are intolerant to other available osteoporosis therapy
    Male osteoporosisCovered for men at high or very high risk for fracture, or after failure or intolerance of available therapy
    Glucocorticoid-induced osteoporosis

    Initial Denosumab Therapy

    Initial Denosumab Therapy

    Initial therapy is covered only when ALL of the following are met for the selected indication.

    • Administration and product

      • The drug is physician administered in an office or hospital outpatient department by a healthcare professional and is not self-administered.
      • The requested product is Prolia, Xgeva, or a listed denosumab biosimilar.
    • Selected covered indication

      • Osteoporosis: The member has postmenopausal, glucocorticoid-induced, or male osteoporosis and meets either the very-high-fracture-risk criteria or the three-year bisphosphonate trial requirement; the member is age 18 or older or has closed epiphyses documented on x-ray; Prolia is not used concurrently with Xgeva; and the dose does not exceed 60 mg every six months.

    Denosumab Reauthorization

    Denosumab Reauthorization

    Reauthorization is available for 12 months when ALL of the following are met.

    Continuation authorization

    • Continued treatment remains within FDA-approved labeling or accepted standards of medical practice.
    • The member continues to meet the applicable indication, dose, administration, and nonconcurrent-use requirements.
    • Treatment continues to be physician administered in an office or hospital outpatient department and is not self-administered.
    • Prolia and Xgeva are not used concurrently.
    • Reauthorization is requested for a 12-month period.

    Prerequisite Therapy

    StepRequirementDetails
    1Complete a three-year trial of bisphosphonate therapy before Prolia or a biosimilar for osteoporosis.Use up to maximally indicated doses; alendronate is preferred. The requirement may be waived when the member has a contraindication or clinically significant adverse effects with both intravenous and oral formulations.
    StepRequirementDetails
    1Use intravenous bisphosphonate therapy before Xgeva for hypercalcemia of malignancy.Coverage requires albumin-corrected calcium greater than 12.5 mg/dL despite IV bisphosphonate therapy within the preceding 30 days.

    Dose and Frequency Limits

    Prolia
    ProductProlia
    Maximum dose60 mg per dose
    Maximum frequencyEvery 6 months by subcutaneous injection
    Xgeva
    ProductXgeva
    Standard schedule120 mg by subcutaneous injection every 4 weeks
    Additional loading dosesFor giant cell tumor of bone and hypercalcemia of malignancy, 120 mg on days 8 and 15 of the first month of therapy is also allowed

    Administration Setting

    Billing Rule

    Physician office administration

    Administer denosumab by a physician in an office setting. The drug must be administered by a healthcare professional and cannot be self-administered.

    • Setting: physician office.
    • Administration: healthcare professional.
    Billing Rule

    Hospital outpatient administration

    Physician administration is also permitted in a hospital outpatient department. Ensure the drug is administered by a healthcare professional and is not self-administered.

    • Setting: hospital outpatient department.
    • Administration: physician or other healthcare professional as specified by the policy.

    Eligible Denosumab Biosimilars

    Billing Rule

    Use recognized denosumab biosimilars appropriately

    The policy recognizes the listed denosumab biosimilars as eligible alternatives to Prolia or Xgeva when the request meets the applicable Prolia or Xgeva indication and authorization criteria.

    • Bilprevda
    • Bildyos
    • Bomyntra
    • Conexxence
    • Osenvelt
    • Stoboclo
    • Jubbonti
    • Wyost
    • Ospomyv
    • Bosaya
    • Aukelso
    • Enoby
    • Xtrenbo
    Policy Summary
    PayerGold Coast Health Plan
    PolicyDenosumab (Prolia, Xgeva, and Biosimilars)
    Policy CodePolicy N/A
    Change TypeAdded covered biosimilars
    Effective DateApril 9, 2026
    Last ReviewMay 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for physician-administered Prolia, Xgeva, or an eligible denosumab biosimilar.
    SourceLink
    On This Page
    Covered Indications and General CriteriaCovered Billing and Clinical CodingAuthorization, Documentation, and Denial RisksClinical BackgroundKey DefinitionsInitial Denosumab TherapyDenosumab ReauthorizationPrerequisite TherapyDose and Frequency LimitsAdministration SettingEligible Denosumab Biosimilars
  1. Prolia is not prescribed concurrently with Xgeva.
  2. Dose does not exceed 60 mg every six months.60 mg every 6 months
  3. Member is age 18 or older or has documentation of closed epiphyses on x-ray.
  4. Xgeva is not prescribed concurrently with Prolia.
  5. Dosing is within the policy limit.120 mg every 4 weeks
  6. Xgeva is not prescribed concurrently with Prolia.
  7. Dose does not exceed 120 mg every four weeks, plus 120 mg on days 8 and 15 of the first month of therapy.120 mg every 4 weeks; additional 120 mg doses on days 8 and 15 of the first month
  8. Xgeva is not prescribed concurrently with Prolia.
  9. Dose does not exceed 120 mg every four weeks, plus 120 mg on days 8 and 15 of the first month of therapy.120 mg every 4 weeks; additional 120 mg doses on days 8 and 15 of the first month
  10. A major osteoporotic fracture, including fracture of the hip, spine, forearm, wrist, or humerus
    Glucocorticoid Exposure
    Prednisone-equivalent dose≥ 7.5 mg daily
    Expected duration≥ 6 months of glucocorticoid use
    Covered populationMen and women with glucocorticoid-induced osteoporosis at high risk of fracture who are initiating or continuing systemic glucocorticoids
    Hypercalcemia of Malignancy
    Albumin-corrected calcium> 12.5 mg/dL
    Prior treatmentCalcium remains above the threshold despite intravenous bisphosphonate therapy
    Treatment timingIV bisphosphonate therapy must have occurred within the last 30 days
  11. Xgeva or biosimilar products are used for multiple myeloma, solid-tumor bone metastasis, giant cell tumor of bone, and hypercalcemia of malignancy.
  12. Coverage duration is initially 6 months, with reauthorization for 12 months; dosing must follow FDA-approved labeling or accepted standards of medical practice.
  13. Step Therapy

    Bisphosphonate Trial Required for Osteoporosis

    For osteoporosis requests, document completion of a three-year bisphosphonate trial at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects occurred with both intravenous and oral formulations.

    • Alendronate is the preferred bisphosphonate.
    • The prerequisite applies to osteoporosis requests for Prolia or a biosimilar.
    • Document the contraindication or clinically significant adverse effects when the three-year trial was not completed.
    Step Therapy

    Document Prior IV Bisphosphonate Failure

    For hypercalcemia of malignancy, document failure of recent intravenous bisphosphonate therapy before requesting Xgeva or a biosimilar.

    • Albumin-corrected calcium must be > 12.5 mg/dL despite IV bisphosphonate therapy in the last 30 days.
    Documentation Required

    Clinical Authorization Documentation

    Submit complete clinical and administrative documentation with the authorization request and reauthorization request. Incomplete documentation may delay review or result in denial.

    • Requested product and biosimilar status, diagnosis, and applicable indication.
    • Physician-administered setting: in-office or HOPD; confirm the drug cannot be self-administered.
    • Relevant specialist involvement, including oncologist prescription or consultation when required.
    • Age 18 years or older, or documentation of closed epiphyses on x-ray.
    • Prior therapy and response or intolerance, including the osteoporosis bisphosphonate prerequisite or hypercalcemia IV bisphosphonate failure when applicable.
    • Clinical risk, disease status, treatment history, laboratory results, requested dose and frequency, and confirmation that the product will not be used concurrently with Prolia and Xgeva.
    • For continuation requests, include response to treatment and the requested coverage period.
    Documentation Required

    Osteoporosis Evidence

    For osteoporosis, document the qualifying diagnosis and objective fracture-risk evidence supporting Prolia or a biosimilar.

    • Diagnosis of postmenopausal osteoporosis (PMO), glucocorticoid-induced osteoporosis (GIO), or male osteoporosis.
    • Very high fracture risk demonstrated by BMD T-score at the hip or spine ≤ -3.5; or BMD T-score at the hip or spine ≤ -2.5 plus a major osteoporotic fracture.
    • Major osteoporotic fractures include hip, spine, forearm, wrist, or humerus.
    • Submit the BMD report and fracture history when used to meet the criterion.
    Documentation Required

    Cancer Fracture-Prevention Evidence

    For prostate or breast cancer fracture prevention, document the qualifying cancer diagnosis, the related treatment, and oncology involvement.

    • Prostate cancer with current androgen-deprivation therapy (ADT), such as leuprolide, bicalutamide, or Nilandron.
    • Breast cancer with current adjuvant endocrine therapy, such as tamoxifen or an aromatase inhibitor including anastrozole, exemestane, or letrozole.
    • Prolia or a biosimilar must be prescribed by or in consultation with an oncologist.
    • Submit cancer diagnosis and treatment records, including the current ADT or adjuvant endocrine therapy.
    Documentation Required

    Oncology Documentation

    For oncology indications, submit documentation establishing the tumor diagnosis, disease status or skeletal risk, treatment context, and required oncologist involvement.

    • Multiple myeloma or bony metastasis from a solid tumor, such as breast, kidney, lung, prostate, or thyroid cancer, with risk for a skeletal-related event.
    • Giant cell tumor of bone with metastatic or unresectable disease, or localized disease when Xgeva is used as a single agent or with interferon alfa or radiation therapy.
    • Hypercalcemia of malignancy with albumin-corrected calcium > 12.5 mg/dL despite IV bisphosphonate therapy in the last 30 days.
    • Document skeletal-related-event risk, such as pathologic fracture, radiation therapy or surgery to bone, or spinal cord compression, when applicable.
    • Xgeva or a biosimilar must be prescribed by or in consultation with an oncologist; provide the oncologist's documentation.
    Denial Risk

    Contraindications May Result in Denial

    Do not administer denosumab when a listed contraindication is present. Requests may be denied for systemic hypersensitivity, preexisting hypocalcemia, or pregnancy.

    • Hypersensitivity to denosumab or any formulation component.
    • Preexisting hypocalcemia.
    • Pregnancy.
    Denial Risk

    Failure to Meet Indication Criteria

    Deny requests that do not meet the applicable indication criteria, including requests for an unsupported product, diagnosis, specialist, age or skeletal-maturity status, concurrent therapy, or clinical requirement.

    • The requested product must be Prolia or a biosimilar for osteoporosis or prostate/breast cancer fracture prevention, or Xgeva or a biosimilar for the specified oncology indications.
    • The diagnosis and required disease status, fracture risk, cancer treatment, or laboratory evidence must be documented.
    • Required oncologist prescription or consultation must be documented for oncology indications.
    • The member must be age 18 years or older or have documentation of closed epiphyses on x-ray.
    • Prolia and Xgeva must not be prescribed concurrently.
    • All indication-specific criteria, including prior bisphosphonate requirements, must be satisfied.
    Denial Risk

    Dose and Frequency Limits

    Requests exceeding the policy dose or frequency limits may be denied. Confirm the requested regimen before submitting authorization.

    • Prolia: no more than 60 mg every six months.
    • Xgeva: no more than 120 mg every four weeks, plus 120 mg on days 8 and 15 of the first month of therapy.
    Denial Risk

    Do Not Use Prolia and Xgeva Concurrently

    Concurrent prescribing of Prolia and Xgeva is not covered and may result in denial. Confirm that the member is not receiving the other denosumab product.

    • Prolia requests must confirm no concurrent Xgeva therapy.
    • Xgeva requests must confirm no concurrent Prolia therapy.
    Denial Risk

    Approved Administration Setting Required

    Denosumab must be physician administered in an office or HOPD and cannot be self-administered. Requests for an unsupported site or self-administration may be denied.

    • Document the planned in-office or HOPD administration setting.
    • Do not submit physician-administered Part B authorization for home or self-administration.
    Covered in men and women at high fracture risk receiving or initiating glucocorticoids equivalent to ≥ 7.5 mg prednisone daily for ≥ 6 months
    Qualifying criteriaVery high fracture risk may be established by a hip or spine BMD T-score ≤ -3.5, or ≤ -2.5 plus a major osteoporotic fracture; alternatively, a three-year bisphosphonate trial may qualify
    Skeletal-Related Event Prevention
    Multiple myelomaPrevention of skeletal-related events in patients with multiple myeloma
    Solid tumorsPrevention of skeletal-related events in patients with bone metastases from solid tumors
    Skeletal-related-event riskExamples include pathologic fracture, radiation therapy or surgery to bone, and spinal cord compression
  14. Cancer-related fracture prevention: The member has prostate cancer receiving androgen-deprivation therapy or breast cancer receiving adjuvant endocrine therapy; treatment is prescribed by or in consultation with an oncologist; the member is age 18 or older or has closed epiphyses documented on x-ray; Prolia is not used concurrently with Xgeva; and the dose does not exceed 60 mg every six months.
  15. Multiple myeloma or solid-tumor bone metastasis: The member has multiple myeloma or bony metastasis from a solid tumor, is at risk for a skeletal-related event, and receives treatment prescribed by or in consultation with an oncologist; the member is age 18 or older or has closed epiphyses documented on x-ray; Xgeva is not used concurrently with Prolia; and dosing is within the policy limit.
  16. Giant cell tumor of bone: The member has metastatic or unresectable giant cell tumor of bone, or localized disease treated with Xgeva alone or with interferon alfa or radiation therapy; treatment is prescribed by or in consultation with an oncologist; the member is age 18 or older or has closed epiphyses documented on x-ray; Xgeva is not used concurrently with Prolia; and dosing does not exceed 120 mg every four weeks plus 120 mg on days 8 and 15 of the first month.
  17. Hypercalcemia of malignancy: The member has hypercalcemia of malignancy; treatment is prescribed by or in consultation with an oncologist; the member is age 18 or older or has closed epiphyses documented on x-ray; albumin-corrected calcium is greater than 12.5 mg/dL despite intravenous bisphosphonate therapy in the last 30 days; Xgeva is not used concurrently with Prolia; and dosing does not exceed 120 mg every four weeks plus 120 mg on days 8 and 15 of the first month.
  18. Authorization conditions

    • The requested dose is within FDA-approved labeling or accepted standards of medical practice.
    • Initial authorization is limited to six months.6 months
  19. 12 months

    The policy specifies the reauthorization duration but does not state additional disease-response criteria.